This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Evaluation of an Intervention on Adherence to Highly Active Antiretroviral Therapy (HAART) in HIV Infected Adults

This study has been terminated.
Information provided by (Responsible Party):
University of Chicago Identifier:
First received: September 12, 2005
Last updated: September 4, 2013
Last verified: September 2013
It is known successful HIV therapy depends on the patients' ability to take their medicine regularly. This study is designed to find out if an intervention designed to help patients remember to take their medication is effective. The intervention consists of a wristwatch that has an alarm to remind patients when to take their medication, a pillbox and three monthly phone calls by a physician. All these experimental measures are meant to improve the ability of patients to take their medicines.

Condition Intervention
HIV Infections Device: pillbox, wristwatch

Study Type: Interventional
Study Design: Intervention Model: Factorial Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of an Intervention (Consisting of an Electronic Reminder Device, Pillboxes, and Monthly Telephone Calls) on Adherence to Highly Active Antiretroviral Therapy (HAART) in HIV Infected Adults

Resource links provided by NLM:

Further study details as provided by University of Chicago:

Primary Outcome Measures:
  • The primary outcome is to determine if the intervention has any effect on adherance with HAART by noting the HIV viral loads of both groups.

Secondary Outcome Measures:
  • To determine if the study's simple and cost effective intervention has a benefit to subjects and if it would stand to benefit other centers that take care of patients with HIV.

Estimated Enrollment: 200
Study Start Date: January 2005
Study Completion Date: March 2007
Primary Completion Date: March 2007 (Final data collection date for primary outcome measure)
  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patient must have HIV to participate
  • patient must be at least 18 years of age or older
  • must have been on HAART for six weeks
  • must have a working telephone number

Exclusion Criteria:

  • patient is HIV negative
  • patient is younger than 18 years of age
  • patient has been on HAART for less than 6 weeks
  • if patient does not have a working telephone number, he/she cannot participate in the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00203853

United States, Illinois
The University of Chicago
Chicago, Illinois, United States, 60637
Sponsors and Collaborators
University of Chicago
Principal Investigator: Jean-Luc Benoit, MD University of Chicago
  More Information

Responsible Party: University of Chicago Identifier: NCT00203853     History of Changes
Other Study ID Numbers: 13640A
Falk Medical Trust Grant
Study First Received: September 12, 2005
Last Updated: September 4, 2013

Keywords provided by University of Chicago:
medication adherance

Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases processed this record on September 21, 2017